Net Cash Provided by (Used in) Financing Activities in USD of Monopar Therapeutics from 2016 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Monopar Therapeutics quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from 2016 to Q1 2025.
  • Monopar Therapeutics Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2025 was -$116K, a 104% decline year-over-year.
  • Monopar Therapeutics annual Net Cash Provided by (Used in) Financing Activities for 2024 was $59.3M, a 2825% increase from 2023.
  • Monopar Therapeutics annual Net Cash Provided by (Used in) Financing Activities for 2023 was $2.03M, a 6067% increase from 2022.
  • Monopar Therapeutics annual Net Cash Provided by (Used in) Financing Activities for 2022 was $32.9K, a 99.7% decline from 2021.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Growth (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Growth (%)

Monopar Therapeutics Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2025 -$116K -$3.3M -104% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-13
Q1 2024 $3.18M +$2.38M +295% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-13
Q1 2023 $805K +$821K Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q1 2022 -$16.7K -$10.9M -100% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q1 2021 $10.9M +$10.4M +2050% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q1 2020 $508K +$522K Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-13
Q1 2019 -$13.9K -$13.9K Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q1 2018 $0 -$990K -100% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-10
Q1 2017 $990K Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-11

Monopar Therapeutics Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $59.3M +$57.3M +2825% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-31
2023 $2.03M +$1.99M +6067% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-31
2022 $32.9K -$10.8M -99.7% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-28
2021 $10.9M +$2.7M +33% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-23
2020 $8.18M -$1.17M -12.5% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-24
2019 $9.35M +$9.55M Jan 1, 2019 Dec 31, 2019 10-K 2021-03-25
2018 -$206K -$9.74M -102% Jan 1, 2018 Dec 31, 2018 10-K 2020-03-27
2017 $9.54M +$8.27M +655% Jan 1, 2017 Dec 31, 2017 10-K 2019-02-26
2016 $1.26M Jan 1, 2016 Dec 31, 2016 10-K 2018-03-26
* An asterisk sign (*) next to the value indicates that the value is likely invalid.